ACTRN12618001805268
Recruiting
未知
The Physiological Changes Following Bronchoscopic Lung Volume Reduction Treatment for Chronic Obstructive Pulmonary Disease (COPD)
niversity of Adelaide0 sites50 target enrollmentNovember 6, 2018
ConditionsChronic Obstructive Pulmonary DiseaseEmphysemaRespiratory physiologyCardiac PhysiologyCor PulmonalePulmonary Vascular ResistanceExercise PhysiologyRespiratory - Chronic obstructive pulmonary diseaseCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemPhysical Medicine / Rehabilitation - Other physical medicine / rehabilitation
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Chronic Obstructive Pulmonary Disease
- Sponsor
- niversity of Adelaide
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Established diagnosis of COPD with hyperinflation: post\-bronchodilator FEV1 \<50% of predicted AND TLC \> 100% AND RV\>175%
- •\- The absence of any collateral ventilation between target lobe and ipsilateral lobe, diagnosed with quantitative CT fissure integrity of \>90% and confirmation of integrity with Chartis measurement.
- •\- Age \>18 and \<75 at the time of enrolment.
- •\- 6\-min walk test distance \>150m following successful completion of a pulmonary rehabilitation program (or equivalent program).
- •\- No evidence of significant coexistent pulmonary pathology on HRCT
- •\- Able to safely undergo sedation or general anesthesia and bronchoscopy
- •\- Cessation of smoking for 3 months prior
Exclusion Criteria
- •Any patient deemed not suitable for EBV insertion based on internationally accepted best\-practice guidelines. Considerations include:
- •\- Significant co\-existent pulmonary pathology
- •\- Severe Hypercapnia (pCO2 \> 60mmHg on room air)
- •\- Unstable cardiovascular disease
- •\- Severe heart failure: EF \<35%
- •\- Unstable cardiac arrhythmia, myocardial infarction or stroke within 6 months
- •\- Severe PAH: RVSP \>45mmHg
- •\- Current Smoker
- •\- 6MWT distance less than 150m post pulmonary rehabilitation or equivalent program
- •\- FEV1 \<15% predicted
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
ung Function Improvement after Bronchoscopic Lung Volume Reduction with Pulmonx Endobronchial Valves used in Treatment of EmphysemaCOPD emphysema10038716NL-OMON42116PulmonX International Sarl24
Recruiting
Phase 4
Study to assess whether Inhalational Bronchodilator given prior to bronchoscopy reduces discomfort due to breathlessness and coughHealth Condition 1: null- Patients with any respiratory disease leading to FEV1/FVC less than 70%CTRI/2013/04/003520Department of Medicine AIIMS50
Completed
Not Applicable
Effects of pre-bronchoscopy administration of intravenous hydrocortisone in patients with chronic obstructive pulmonary diseasechronic obstructive pulmonary disease.chronic lower respiratory diseasesJ40, J41,IRCT2015110922566N1Vice chancellor for research,Kerman University of Medical Sciences90
Recruiting
Not Applicable
Comparative study of fibroptic bronchoscopic with two method: midazolam base versus lidocaine baseIRCT20110103005536N8Artesh University of Medical Sciences140
Not yet recruiting
Not Applicable
Effect of therapeutic bronchoscopy in critically ill patients in terms of oxygenation and ventilatory mechanicsHealth Condition 1: J22- Unspecified acute lower respiratory infectionHealth Condition 2: J22- Unspecified acute lower respiratory infectionCTRI/2023/09/057440Self